Tocagen’s brain cancer treatment fails late-stage studyAnalysts, Blockbusters, Brain Cancer, Clinical Trials, Glioblastoma, Immunotherapies, R&D, Recurrent High Grade Glioma (RHGG), SharesTocagen Inc.’s shares fell nearly 80 percent after the company’s experimental treatment failed to extend life of brain cancer patients in a study, the latest in a series of setbacks for patients awaiting new treatment options for the condition. Read more September 12, 2019/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2019-09-12 06:23:592019-09-12 13:35:15Tocagen’s brain cancer treatment fails late-stage study